MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
107.92
+0.56
+0.52%
Opening 12:24 06/21 EDT
OPEN
107.84
PREV CLOSE
107.36
HIGH
108.89
LOW
107.29
VOLUME
269.86K
TURNOVER
0
52 WEEK HIGH
146.70
52 WEEK LOW
103.01
MARKET CAP
6.81B
P/E (TTM)
22.26
1D
5D
1M
3M
1Y
5Y
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Seeking Alpha · 4h ago
Maintaining a Buy Rating: Jazz Pharmaceuticals’ Solid Prospects Despite Clinical Trial Setbacks
TipRanks · 5h ago
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Jazz Pharmaceuticals (JAZZ) and Legend Biotech (LEGN)
TipRanks · 6h ago
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Barclays
Barclays analyst Balaji Prasad maintained a Buy rating on Jazz Pharmaceuticals (JAZZ) The company has an analyst consensus of Strong Buy with a price target of $200.00. The company’s shares closed yesterday at $107.36.
TipRanks · 8h ago
BUZZ-U.S. STOCKS ON THE MOVE-Allstate, MicroStrategy, AutoZone
The S&P 500 and the Nasdaq hit record highs on Thursday. The Dow Jones Industrial Average was up 0.48% at 39,019.33. The top three Nasdaq percentage gainers of the day were Nvidia, Accenture and Gilead Sciences.
Reuters · 23h ago
Stocks are Mixed in Midday Trade
NASDAQ · 1d ago
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Jazz Pharmaceuticals plc released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide in adult patients with essential tremor. The drug is an investigational, highly selective and state-dependent modulator of T-type calcium channels.
Benzinga · 1d ago
S&P 500 and Nasdaq 100 Fall from Record Highs as Chip Stocks Retreat
S&P 500 and Nasdaq 100 post new record highs on strength in chip stocks. Stocks settled mixed on Thursday after weaker-than-expected US economic reports. Chipmakers initially rallied on strong Q1 earnings results, but Qualcomm plunges after cutting revenue estimate. T-note prices recovered from their worst levels Thursday on dovish outlook for Fed.
Barchart · 1d ago
More
About JAZZ
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Webull offers Jazz Pharmaceuticals PLC stock information, including NASDAQ: JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.